Walleye Capital’s Humacyte Inc Warrant HUMAW Stock Holding History

Walleye Capital’s Portfolio HUMAW Stock Details HUMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-108,901	Closed	-$45.3K	–	5600
2023 Q4	$45.3K	Sell	108,901 -17,525	-14%	-$8.61K	﹤0.01%	4328
2023 Q3	$90.7K	Sell	126,426 -21,825	-15%	-$17K	﹤0.01%	3979
2023 Q2	$108K	Buy	+148,251	New	+$120K	﹤0.01%	3396

Other funds holding HUMAW

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Walleye Capital's HUMAW Position: Q1 2024 in Review

Walleye Capital sold out of Humacyte Inc Warrant (HUMAW) in Q1 2024, closing a stake of 108,901 shares — an estimated $45.3K sold.

Walleye Capital first reported a position in HUMAW in Q2 2023 and held it in 3 quarters. The position peaked at $108K in Q2 2023. 6 funds tracked by Wall St. Rank hold HUMAW as of Q1 2024.

Walleye Capital reported no remaining Humacyte Inc Warrant position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 108,901 Humacyte Inc Warrant shares in Q1 2024, an estimated $45.3K.
Walleye Capital first reported a position in Humacyte Inc Warrant in Q2 2023 and held it in 3 quarters.
Walleye Capital's Humacyte Inc Warrant position peaked at $108K in Q2 2023.
6 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.